Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer: Insight into the survival paradox

Ho Seung Kim, Kyeong Min Kim, Sat Byol Lee, Ga Ram Kim, Yoon Dae Han, Min Soo Cho, Hyuk Hur, Kang Young Lee, Nam Kyu Kim, Byung Soh Min

Research output: Contribution to journalArticle

Abstract

Background: A survival paradox of stage IIB/IIC and IIIA colon cancer has been consistently observed throughout revisions of the TNM system. This study aimed to understand this paradox with clinicopathological and molecular differences. Methods: Clinicopathological characteristics of patients with pathologically confirmed stage IIB/IIC or IIIA colon cancer were retrospectively reviewed from a database. Publicly available molecular data were retrieved, and intrinsic subtypes were identified and subjected to gene sets enrichment analysis (GSEA). Results: Among the 159 patients included in the clinicopathological analysis, those at stage IIB/IIC had worse 3-year disease-free and overall survival than those at stage IIIA (59.3% vs 91.7%, P < 0.001 and 82.7% vs 98.5%, P < 0.001, respectively), even after adjusting for confounding factors. Data of 95 patients were retrieved from public databases, demonstrating a higher frequency of the microsatellite instable subtype in stage IIB/IIC. The consensus molecular subtype distribution pattern differed between the groups. The GSEA further suggested the protumor inflammatory reaction might be more prominent in stage IIB/IIC. Conclusions: The survival paradox in colon cancer was confirmed and appears to be a multifactorial phenomenon not attributed to a single clinicopathologic factor. However, the greater molecular heterogeneity in stage IIB/IIC could contribute to the poor prognosis.

Original languageEnglish
Pages (from-to)423-430
Number of pages8
JournalJournal of surgical oncology
Volume120
Issue number3
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Colonic Neoplasms
Survival
Databases
Microsatellite Repeats
Genes
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Kim, Ho Seung ; Kim, Kyeong Min ; Lee, Sat Byol ; Kim, Ga Ram ; Han, Yoon Dae ; Cho, Min Soo ; Hur, Hyuk ; Lee, Kang Young ; Kim, Nam Kyu ; Min, Byung Soh. / Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer : Insight into the survival paradox. In: Journal of surgical oncology. 2019 ; Vol. 120, No. 3. pp. 423-430.
@article{f7c2cc35242a453a982c810f41b9e67e,
title = "Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer: Insight into the survival paradox",
abstract = "Background: A survival paradox of stage IIB/IIC and IIIA colon cancer has been consistently observed throughout revisions of the TNM system. This study aimed to understand this paradox with clinicopathological and molecular differences. Methods: Clinicopathological characteristics of patients with pathologically confirmed stage IIB/IIC or IIIA colon cancer were retrospectively reviewed from a database. Publicly available molecular data were retrieved, and intrinsic subtypes were identified and subjected to gene sets enrichment analysis (GSEA). Results: Among the 159 patients included in the clinicopathological analysis, those at stage IIB/IIC had worse 3-year disease-free and overall survival than those at stage IIIA (59.3{\%} vs 91.7{\%}, P < 0.001 and 82.7{\%} vs 98.5{\%}, P < 0.001, respectively), even after adjusting for confounding factors. Data of 95 patients were retrieved from public databases, demonstrating a higher frequency of the microsatellite instable subtype in stage IIB/IIC. The consensus molecular subtype distribution pattern differed between the groups. The GSEA further suggested the protumor inflammatory reaction might be more prominent in stage IIB/IIC. Conclusions: The survival paradox in colon cancer was confirmed and appears to be a multifactorial phenomenon not attributed to a single clinicopathologic factor. However, the greater molecular heterogeneity in stage IIB/IIC could contribute to the poor prognosis.",
author = "Kim, {Ho Seung} and Kim, {Kyeong Min} and Lee, {Sat Byol} and Kim, {Ga Ram} and Han, {Yoon Dae} and Cho, {Min Soo} and Hyuk Hur and Lee, {Kang Young} and Kim, {Nam Kyu} and Min, {Byung Soh}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jso.25515",
language = "English",
volume = "120",
pages = "423--430",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer : Insight into the survival paradox. / Kim, Ho Seung; Kim, Kyeong Min; Lee, Sat Byol; Kim, Ga Ram; Han, Yoon Dae; Cho, Min Soo; Hur, Hyuk; Lee, Kang Young; Kim, Nam Kyu; Min, Byung Soh.

In: Journal of surgical oncology, Vol. 120, No. 3, 01.01.2019, p. 423-430.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinicopathological and biomolecular characteristics of stage IIB/IIC and stage IIIA colon cancer

T2 - Insight into the survival paradox

AU - Kim, Ho Seung

AU - Kim, Kyeong Min

AU - Lee, Sat Byol

AU - Kim, Ga Ram

AU - Han, Yoon Dae

AU - Cho, Min Soo

AU - Hur, Hyuk

AU - Lee, Kang Young

AU - Kim, Nam Kyu

AU - Min, Byung Soh

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: A survival paradox of stage IIB/IIC and IIIA colon cancer has been consistently observed throughout revisions of the TNM system. This study aimed to understand this paradox with clinicopathological and molecular differences. Methods: Clinicopathological characteristics of patients with pathologically confirmed stage IIB/IIC or IIIA colon cancer were retrospectively reviewed from a database. Publicly available molecular data were retrieved, and intrinsic subtypes were identified and subjected to gene sets enrichment analysis (GSEA). Results: Among the 159 patients included in the clinicopathological analysis, those at stage IIB/IIC had worse 3-year disease-free and overall survival than those at stage IIIA (59.3% vs 91.7%, P < 0.001 and 82.7% vs 98.5%, P < 0.001, respectively), even after adjusting for confounding factors. Data of 95 patients were retrieved from public databases, demonstrating a higher frequency of the microsatellite instable subtype in stage IIB/IIC. The consensus molecular subtype distribution pattern differed between the groups. The GSEA further suggested the protumor inflammatory reaction might be more prominent in stage IIB/IIC. Conclusions: The survival paradox in colon cancer was confirmed and appears to be a multifactorial phenomenon not attributed to a single clinicopathologic factor. However, the greater molecular heterogeneity in stage IIB/IIC could contribute to the poor prognosis.

AB - Background: A survival paradox of stage IIB/IIC and IIIA colon cancer has been consistently observed throughout revisions of the TNM system. This study aimed to understand this paradox with clinicopathological and molecular differences. Methods: Clinicopathological characteristics of patients with pathologically confirmed stage IIB/IIC or IIIA colon cancer were retrospectively reviewed from a database. Publicly available molecular data were retrieved, and intrinsic subtypes were identified and subjected to gene sets enrichment analysis (GSEA). Results: Among the 159 patients included in the clinicopathological analysis, those at stage IIB/IIC had worse 3-year disease-free and overall survival than those at stage IIIA (59.3% vs 91.7%, P < 0.001 and 82.7% vs 98.5%, P < 0.001, respectively), even after adjusting for confounding factors. Data of 95 patients were retrieved from public databases, demonstrating a higher frequency of the microsatellite instable subtype in stage IIB/IIC. The consensus molecular subtype distribution pattern differed between the groups. The GSEA further suggested the protumor inflammatory reaction might be more prominent in stage IIB/IIC. Conclusions: The survival paradox in colon cancer was confirmed and appears to be a multifactorial phenomenon not attributed to a single clinicopathologic factor. However, the greater molecular heterogeneity in stage IIB/IIC could contribute to the poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85070850624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070850624&partnerID=8YFLogxK

U2 - 10.1002/jso.25515

DO - 10.1002/jso.25515

M3 - Article

C2 - 31134644

AN - SCOPUS:85070850624

VL - 120

SP - 423

EP - 430

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -